Degenerative Hip Joint DiseasePost-traumatic OsteoarthritisHip ArthritisFemoral Neck FracturesAvascular Necrosis of the Femoral HeadFailure of Prosthetic Joint Implant
Investigational drug(s) / intervention(s)
Total hip arthroplasty (primary or revision)
Total hip arthroplasty (primary or revision): Total hip arthroplasty with at least one medical device from the SYMBOL range
Study summary
The purpose of this post-market clinical follow up study is to assess the safety and effectiveness of the SYMBOL range of medical devices. The study will evaluate the outcome of Total Hip Arthroplasty using medical devices from SYMBOL range over a period of 10 years.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Patient age \> 18 years at implantation.
* Patient who will undergo, during the study's period of inclusion, a total hip arthroplasty (primary or revision) with at least one SYMBOL medical device (DEDIENNE Santé).
* Patient informed of his/her participation and willing to participate in the study.
* Patient able to read, write and understand French.
Exclusion Criteria:
* Patient deprived of freedom, under guardianship/curatorship or placed under judicial protection
* Patient unable to follow study procedures.
* Patient who has already been included in the study for a total hip arthroplasty (primary or revision) with at least one SYMBOL medical device.
Primary outcome measure(s)
Survivorship of 13 individual SYMBOL orthopaedic components — 10 years post-operative The survival rate of an orthopaedic implant will be calculated on the basis of the first occurrence of implant revision from any cause.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
